# Signals Article on Putative Target Q9BXS0 for Alzheimer Disease
Background
The protein encoded by the putative target Q9BXS0, also known as "Uncharacterized protein," has emerged as a candidate of interest in the context of Alzheimer disease (AD). Preliminary data suggest that Q9BXS0 may play a role in neurodegenerative processes, warranting further investigation into its therapeutic potential. Despite its presence in expression-profiling studies, there appears to be a lack of clinical development, as no Phase 1 or higher clinical programs are currently registered for this target. This gap in the literature presents an opportunity for hypothesis-generating research to explore Q9BXS0's involvement in AD.Data-mining rationale
The rationale for investigating Q9BXS0 stems from a comprehensive analysis of publicly available data. By cross-referencing UniProt's reviewed human entries for "Alzheimer disease" against 353 microarray datasets available in the NCBI Gene Expression Omnibus (GEO), we identified Q9BXS0 as a candidate of interest. The analysis revealed that this protein is consistently expressed across various studies, yet it has not been prioritized for clinical exploration. Notably, the datasets utilized in this analysis include GDS:200303974, GDS:200318045, GDS:200317145, GDS:200222333, and GDS:200222332, which may contain valuable insights into its role in AD.Why prior analyses may have missed this
Many of the GEO datasets that include Q9BXS0 predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which allows for more robust multiple-testing corrections. This limitation may have led to an underappreciation of the significance of Q9BXS0 in the context of AD. The absence of a clinical program further suggests that the potential of this candidate may have been overlooked due to methodological constraints in earlier analyses.Reasoning for further validation
To further elucidate the role of Q9BXS0 in Alzheimer disease, we propose the following experimental approaches: 1. **Re-analyze the matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater statistical rigor. 2. **Validate the top differentially-expressed genes** associated with Q9BXS0 through quantitative PCR (qPCR) in an independent cohort to confirm expression changes. 3. **Check tissue specificity** of Q9BXS0 expression using resources such as the GTEx database and the Human Protein Atlas to determine its relevance in brain tissue compared to other tissues. 4. **Run pathway analysis** using STRING and OmniPath to contextualize Q9BXS0 within relevant biological pathways and networks associated with Alzheimer disease. 5. **If validated**, assess the druggability of Q9BXS0 by utilizing databases such as DGIdb and ChEMBL to explore potential therapeutic interventions targeting this candidate.References
- UniProt: Q9BXS0
- UniProt: P05067
- UniProt: Q12830
- UniProt: P10636
- UniProt: Q92673
- GEO Accession: GDS:200303974
- GEO Accession: GDS:200318045
- GEO Accession: GDS:200317145
- GEO Accession: GDS:200222333
- GEO Accession: GDS:200222332
*This article is an AI-curated commentary and does not claim peer-review status.*